064550.KQ
SellFallen FavouriteBioneer Corporation · $156M · Avg Vol: $5M/d
Fallen Favourite: A good business, still expensive, and the price is falling.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT BIONEER CORPORATION
Read
Bioneer Corporation is a pioneer in South Korean biotechnology, specializing in molecular diagnostics, synthetic biology, and RNA interference (RNAi) therapeutics. The company's competitive advantage is anchored in its vertically integrated business model, manufacturing its own raw materials, diagnostic reagents, and automated PCR instruments. It is a leading domestic biotechnology firm expanding globally into molecular diagnostics and novel RNA-based therapeutics.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 218.4B | 263.2B | 294.0B | 330.1B | 14.8% | 292.4B |
| EPS (KRW) | 468.00 | -410.00 | -798.00 | -109.00 | — | -106.92 |
| Shares | 25.8M | 25.8M | 25.8M | 25.8M | 0.0% | 25.8M |
| Debt | 27.9B | 44.6B | 73.7B | 106.4B | 56.3% | 94.2B |
| Equity | 236.0B | 223.9B | 213.9B | 209.7B | -3.9% | — |
| Op CF | 8.8B | 4.1B | -13.5B | 10.3B | 5.5% | 9.2B |
| Inv CF | -19.1B | -13.5B | -21.9B | -35.3B | — | — |
| Fin CF | 4.7B | 14.1B | 26.1B | 32.6B | — | — |
Swung more than 84% of stocks we rank over the past year (71% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.